BRAF and central nervous system cancer: Monotherapy with a MEK inhibitor showed promising outcomes in pLGG with KIAA1549::BRAF fusion or NF1 loss of function.5 Meanwhile, dual therapy with dabrafenib and trametinib was found to be more effective and safe than standard chemotherapy with carboplatin plus vincristine as first-line therapy in pediatric patients with BRAF V600 mutant low-grade gliomas.4